Sino Biopharmaceutical (1177) H2 2024 earnings summary

Executive summary

• Revenue rose 10.2% year-over-year to RMB 28.87bn in 2024, with profit attributable to owners surging 50.1% to RMB 3.50bn, driven by innovative products and a major asset disposal.

• Adjusted non-HKFRS profit increased 33.5% to RMB 3.46bn.

• Innovative product sales grew 21.9%, with new product sales up 25.4%.

• Maintained strong financial position with increased fund reserves, consistent dividend growth, and recommended final dividend of HK4 cents per share.

• Expanded R&D investment, focusing on high-yield innovative pipeline and core therapeutic areas.

Financial highlights

• Gross profit margin improved to 81.5% in 2024 from 80.1% in 2023.

• SG&A expenses as a percentage of revenue declined to 42.1% in 2024.

• R&D expenses as a percentage of revenue: 17.6%–19.0% in 2024.

• Fund reserve/cash and bank balances plus wealth management products totaled RMB 24.1bn at year-end, with net cash at RMB 14.4bn.

• Basic EPS (adjusted non-HKFRS) rose 35.3% to RMB 18.90 cents.

Outlook and guidance

• Over 30 innovative products expected to launch by 2027, with innovative product revenue to exceed 55% of total.

• Multiple blockbuster launches and major clinical data readouts anticipated in 2025–2027 across core therapeutic areas.

• Digitalization, AI integration, and globalization strategy to drive operational efficiency and international expansion.

• Generic drugs expected to maintain positive growth; innovative product revenue share to continue rising.